-
1
-
-
84855792427
-
Cancer statistics
-
Siegel, R., Naishadham, D., & Jemal, A. (2012). Cancer statistics. CA A Cancer Journal for Clinicians, 62, 10-29.
-
(2012)
CA a Cancer Journal for Clinicians
, vol.62
, pp. 10-29
-
-
Siegel, R.1
Naishadham, D.2
Jemal, A.3
-
2
-
-
57849151139
-
Outcomes for intermediate risk prostate cancer: Are there advantages for surgery, external radiation, or brachytherapy?
-
Klein, E. A., Ciezki, J., Kupelian, P. A., & Mahadevan, A. (2009). Outcomes for intermediate risk prostate cancer: are there advantages for surgery, external radiation, or brachytherapy? Urologic Oncology, 27, 67-71.
-
(2009)
Urologic Oncology
, vol.27
, pp. 67-71
-
-
Klein, E.A.1
Ciezki, J.2
Kupelian, P.A.3
Mahadevan, A.4
-
4
-
-
68049140791
-
Starving the addiction: New opportunities for durable suppression of AR signaling in prostate cancer
-
Knudsen, K. E., & Scher, H. I. (2009). Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer. Clinical Cancer Research, 15, 4792-4798.
-
(2009)
Clinical Cancer Research
, vol.15
, pp. 4792-4798
-
-
Knudsen, K.E.1
Scher, H.I.2
-
5
-
-
34248169161
-
Initial hormonal management of Androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 Update of an American society of clinical oncology practice guideline
-
DOI 10.1200/JCO.2006.10.1949
-
Loblaw, D. A., Virgo, K. S., Nam, R., et al. (2007). Initial hormonal management of androgen-sensitivemetastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. Journal of Clinical Oncology, 25, 1596-1605. (Pubitemid 46733088)
-
(2007)
Journal of Clinical Oncology
, vol.25
, Issue.12
, pp. 1596-1605
-
-
Loblaw, D.A.1
Virgo, K.S.2
Nam, R.3
Somerfield, M.R.4
Ben-Josef, E.5
Mendelson, D.S.6
Middleton, R.7
Sharp, S.A.8
Smith, T.J.9
Talcott, J.10
Taplin, M.11
Vogelzang, N.J.12
Wade III, J.L.13
Bennett, C.L.14
Scher, H.I.15
-
6
-
-
45849138558
-
Hormonal approaches in prostate cancer: Application in the contemporary prostate cancer patient
-
DOI 10.1016/j.urolonc.2007.11.003, PII S1078143907002608
-
Beekman, K. W., & Hussain, M. (2008). Hormonal approaches in prostate cancer: application in the contemporary prostate cancer patient. Urologic Oncology, 26, 415-419. (Pubitemid 351885377)
-
(2008)
Urologic Oncology: Seminars and Original Investigations
, vol.26
, Issue.4
, pp. 415-419
-
-
Beekman, K.W.1
Hussain, M.2
-
7
-
-
33644698567
-
Management of advanced prostate cancer after first-line chemotherapy
-
DOI 10.1200/JCO.2005.03.1435
-
Berthold, D. R., Sternberg, C. N., & Tannock, I. F. (2005). Management of advanced prostate cancer after first-line chemotherapy. Journal of Clinical Oncology, 23, 8247-8252. (Pubitemid 46211562)
-
(2005)
Journal of Clinical Oncology
, vol.23
, Issue.32
, pp. 8247-8252
-
-
Berthold, D.R.1
Sternberg, C.N.2
Tannock, I.F.3
-
8
-
-
0032761807
-
Chemotherapy for advanced hormone refractory prostate cancer
-
Petrylak, D. P. (1999). Chemotherapy for advanced hormone refractory prostate cancer. Urology, 54, 30-35.
-
(1999)
Urology
, vol.54
, pp. 30-35
-
-
Petrylak, D.P.1
-
9
-
-
33746021720
-
Chemotherapy for advanced prostate cancer: Docetaxel and beyond
-
Dreicer, R. (2006). Chemotherapy for advanced prostate cancer: docetaxel and beyond. Hematology/Oncology Clinics of North America, 20, 935-946. x.
-
(2006)
Hematology/Oncology Clinics of North America
, vol.20
-
-
Dreicer, R.1
-
10
-
-
77952554163
-
Partners in crime: Deregulation of AR activity and androgen synthesis in prostate cancer
-
Knudsen, K. E., & Penning, T. M. (2010). Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer. Trends in Endocrinology and Metabolism, 21, 315-324.
-
(2010)
Trends in Endocrinology and Metabolism
, vol.21
, pp. 315-324
-
-
Knudsen, K.E.1
Penning, T.M.2
-
11
-
-
42949134229
-
Maximal androgen blockade for the treatment of metastatic prostate cancer - A systematic review
-
Lukka, H., Waldron, T., Klotz, L., Winquist, E., & Trachtenberg, J. (2006). Maximal androgen blockade for the treatment of metastatic prostate cancer - a systematic review. Current Oncology, 13, 81-93.
-
(2006)
Current Oncology
, vol.13
, pp. 81-93
-
-
Lukka, H.1
Waldron, T.2
Klotz, L.3
Winquist, E.4
Trachtenberg, J.5
-
12
-
-
58049196759
-
Mechanisms mediating androgen receptor reactivation after castration
-
Yuan, X., & Balk, S. P. (2009). Mechanisms mediating androgen receptor reactivation after castration. Urologic Oncology, 27, 36-41.
-
(2009)
Urologic Oncology
, vol.27
, pp. 36-41
-
-
Yuan, X.1
Balk, S.P.2
-
13
-
-
84901827161
-
Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis
-
doi:10.1038/onc.2013.235
-
Yuan, X., Cai, C., Chen, S., Yu, Z., & Balk, S. P. (2013). Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis. Oncogene. doi:10.1038/onc.2013.235.
-
(2013)
Oncogene
-
-
Yuan, X.1
Cai, C.2
Chen, S.3
Yu, Z.4
Balk, S.P.5
-
14
-
-
84856927346
-
Bone scan index: A quantitative treatment response biomarker for castration-resistant metastatic prostate cancer
-
Dennis, E. R., Jia, X., Mezheritskiy, I. S., et al. (2012). Bone scan index: a quantitative treatment response biomarker for castration-resistant metastatic prostate cancer. Journal of Clinical Oncology, 30, 519-524.
-
(2012)
Journal of Clinical Oncology
, vol.30
, pp. 519-524
-
-
Dennis, E.R.1
Jia, X.2
Mezheritskiy, I.S.3
-
15
-
-
12344337580
-
Hormonal, cellular, and molecular regulation of normal and neoplastic prostatic development
-
DOI 10.1016/j.jsbmb.2004.10.017, PII S0960076004003632, Steroids and Prostate Cancer
-
Cunha, G. R., Ricke, W., Thomson, A., et al. (2004). Hormonal, cellular, and molecular regulation of normal and neoplastic prostatic development. Journal of Steroid Biochemistry and Molecular Biology, 92, 221-236. (Pubitemid 40136583)
-
(2004)
Journal of Steroid Biochemistry and Molecular Biology
, vol.92
, Issue.4
, pp. 221-236
-
-
Cunha, G.R.1
Ricke, W.2
Thomson, A.3
Marker, P.C.4
Risbridger, G.5
Hayward, S.W.6
Wang, Y.Z.7
Donjacour, A.A.8
Kurita, T.9
-
16
-
-
84857371687
-
The AR dependent cell cycle: Mechanisms and cancer relevance
-
Schiewer, M. J., Augello, M. A., & Knudsen, K. E. (2012). The AR dependent cell cycle: mechanisms and cancer relevance. Molecular and Cellular Endocrinology, 352, 34-45.
-
(2012)
Molecular and Cellular Endocrinology
, vol.352
, pp. 34-45
-
-
Schiewer, M.J.1
Augello, M.A.2
Knudsen, K.E.3
-
17
-
-
37349109417
-
Prereceptor regulation of the androgen receptor
-
Penning, T. M., Jin, Y., Rizner, T. L., & Bauman, D. R. (2008). Prereceptor regulation of the androgen receptor. Molecular and Cellular Endocrinology, 281, 1-8.
-
(2008)
Molecular and Cellular Endocrinology
, vol.281
, pp. 1-8
-
-
Penning, T.M.1
Jin, Y.2
Rizner, T.L.3
Bauman, D.R.4
-
18
-
-
0034714276
-
Structural evidence for ligand specificity in the binding domain of the human androgen receptor. Implications for pathogenic gene mutations
-
Matias, P. M., Donner, P., Coelho, R., et al. (2000). Structural evidence for ligand specificity in the binding domain of the human androgen receptor. Implications for pathogenic gene mutations. Journal of Biological Chemistry, 275, 26164-26171.
-
(2000)
Journal of Biological Chemistry
, vol.275
, pp. 26164-26171
-
-
Matias, P.M.1
Donner, P.2
Coelho, R.3
-
19
-
-
0035942197
-
Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone
-
DOI 10.1073/pnas.081565498
-
Sack, J. S., Kish, K. F., Wang, C., et al. (2001). Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone. Proceedings of the National Academy of Sciences of the United States of America, 98, 4904-4909. (Pubitemid 32397055)
-
(2001)
Proceedings of the National Academy of Sciences of the United States of America
, vol.98
, Issue.9
, pp. 4904-4909
-
-
Sack, J.S.1
Kish, K.F.2
Wang, C.3
Attar, R.M.4
Kiefer, S.E.5
An, Y.6
Wu, G.Y.7
Scheffler, J.E.8
Salvati, M.E.9
Krystek Jr., S.R.10
Weinmann, R.11
Einspahr, H.M.12
-
20
-
-
55049086227
-
The contribution of different androgen receptor domains to receptor dimerization and signaling
-
Centenera, M. M., Harris, J. M., Tilley, W. D., & Butler, L. M. (2008). The contribution of different androgen receptor domains to receptor dimerization and signaling. Molecular Endocrinology, 22, 2373-2382.
-
(2008)
Molecular Endocrinology
, vol.22
, pp. 2373-2382
-
-
Centenera, M.M.1
Harris, J.M.2
Tilley, W.D.3
Butler, L.M.4
-
21
-
-
84857360697
-
Post-translational modification of the androgen receptor
-
Gioeli, D., & Paschal, B. M. (2012). Post-translational modification of the androgen receptor. Molecular and Cellular Endocrinology, 352, 70-78.
-
(2012)
Molecular and Cellular Endocrinology
, vol.352
, pp. 70-78
-
-
Gioeli, D.1
Paschal, B.M.2
-
22
-
-
84869135796
-
Regulation of the androgen receptor by post-translational modifications
-
Coffey, K., & Robson, C. N. (2012). Regulation of the androgen receptor by post-translational modifications. Journal of Endocrinology, 215, 221-237.
-
(2012)
Journal of Endocrinology
, vol.215
, pp. 221-237
-
-
Coffey, K.1
Robson, C.N.2
-
24
-
-
1042269786
-
Effect of orchiectomy and irradiation on cancer of the prostate
-
Huggins, C. (1942). Effect of orchiectomy and irradiation on cancer of the prostate. Annals of Surgery, 115, 1192-1200.
-
(1942)
Annals of Surgery
, vol.115
, pp. 1192-1200
-
-
Huggins, C.1
-
25
-
-
84894406301
-
The diagnosis of cancer of the prostate including the interpretation of serum phosphatase values
-
Huggins, C. (1943). The diagnosis of cancer of the prostate including the interpretation of serum phosphatase values. Bulletin of the New York Academy of Medicine, 19, 195-200.
-
(1943)
Bulletin of the New York Academy of Medicine
, vol.19
, pp. 195-200
-
-
Huggins, C.1
-
26
-
-
79956135979
-
The treatment of cancer of the prostate: (The 1943 address in surgery before the Royal College of Physicians and Surgeons of Canada)
-
Huggins, C. (1944). The treatment of cancer of the prostate: (the 1943 address in surgery before the Royal College of Physicians and Surgeons of Canada). Canadian Medical Association Journal, 50, 301-307.
-
(1944)
Canadian Medical Association Journal
, vol.50
, pp. 301-307
-
-
Huggins, C.1
-
27
-
-
44649169622
-
Testosterone surge: Rationale for gonadotropin-releasing hormone blockers?
-
van Poppel, H., & Nilsson, S. (2008). Testosterone surge: rationale for gonadotropin-releasing hormone blockers? Urology, 71, 1001-1006.
-
(2008)
Urology
, vol.71
, pp. 1001-1006
-
-
Van Poppel, H.1
Nilsson, S.2
-
28
-
-
0034659787
-
Hormone therapy for patients with prostate carcinoma
-
Klotz, L. (2000). Hormone therapy for patients with prostate carcinoma. Cancer, 88, 3009-3014.
-
(2000)
Cancer
, vol.88
, pp. 3009-3014
-
-
Klotz, L.1
-
29
-
-
0344378213
-
Time to normalization of serumtestosterone after 3-month luteinizing hormone-releasing hormone agonist administered in the neoadjuvant setting: Implications for dosing schedule and neoadjuvant study consideration
-
Oefelein, M. G. (1998). Time to normalization of serumtestosterone after 3-month luteinizing hormone-releasing hormone agonist administered in the neoadjuvant setting: implications for dosing schedule and neoadjuvant study consideration. Journal of Urology, 160, 1685-1688.
-
(1998)
Journal of Urology
, vol.160
, pp. 1685-1688
-
-
Oefelein, M.G.1
-
30
-
-
79956103537
-
Outsmarting androgen receptor: Creative approaches for targeting aberrant androgen signaling in advanced prostate cancer
-
Knudsen, K. E., & Kelly, W. K. (2011). Outsmarting androgen receptor: creative approaches for targeting aberrant androgen signaling in advanced prostate cancer. Expert Review of Endocrinology and Metabolism, 6, 483-493.
-
(2011)
Expert Review of Endocrinology and Metabolism
, vol.6
, pp. 483-493
-
-
Knudsen, K.E.1
Kelly, W.K.2
-
31
-
-
80054021222
-
Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors
-
Cai, C., Chen, S., Ng, P., et al. (2011). Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. Cancer Research, 71, 6503-6513.
-
(2011)
Cancer Research
, vol.71
, pp. 6503-6513
-
-
Cai, C.1
Chen, S.2
Ng, P.3
-
32
-
-
49249119358
-
Maintenance of intratumoral androgens in metastatic prostate cancer: A mechanism for castration-resistant tumor growth
-
Montgomery, R. B., Mostaghel, E. A., Vessella, R., et al. (2008). Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Research, 68, 4447-4454.
-
(2008)
Cancer Research
, vol.68
, pp. 4447-4454
-
-
Montgomery, R.B.1
Mostaghel, E.A.2
Vessella, R.3
-
33
-
-
79953320228
-
New strategies in metastatic prostate cancer: Targeting the androgen receptor signaling pathway
-
Attard, G., Richards, J., & de Bono, J. S. (2011). New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway. Clinical Cancer Research, 17, 1649-1657.
-
(2011)
Clinical Cancer Research
, vol.17
, pp. 1649-1657
-
-
Attard, G.1
Richards, J.2
De Bono, J.S.3
-
34
-
-
79957443342
-
Abiraterone and increased survival in metastatic prostate cancer
-
de Bono, J. S., Logothetis, C. J., Molina, A., et al. (2011). Abiraterone and increased survival in metastatic prostate cancer. New England Journal of Medicine, 364, 1995-2005.
-
(2011)
New England Journal of Medicine
, vol.364
, pp. 1995-2005
-
-
De Bono, J.S.1
Logothetis, C.J.2
Molina, A.3
-
35
-
-
84863393126
-
Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone
-
Efstathiou, E., Titus, M., Tsavachidou, D., et al. (2012). Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone. Journal of Clinical Oncology, 30, 637-643.
-
(2012)
Journal of Clinical Oncology
, vol.30
, pp. 637-643
-
-
Efstathiou, E.1
Titus, M.2
Tsavachidou, D.3
-
36
-
-
84883741726
-
Overview of the latest treatments for castration-resistant prostate cancer
-
Bishr, M., & Saad, F. (2013). Overview of the latest treatments for castration-resistant prostate cancer. Nature Reviews. Urology, 10(9), 522-528.
-
(2013)
Nature Reviews. Urology
, vol.10
, Issue.9
, pp. 522-528
-
-
Bishr, M.1
Saad, F.2
-
37
-
-
79959233647
-
Targeting continued androgen receptor signaling in prostate cancer
-
Massard, C., & Fizazi, K. (2011). Targeting continued androgen receptor signaling in prostate cancer. Clinical Cancer Research, 17, 3876-3883.
-
(2011)
Clinical Cancer Research
, vol.17
, pp. 3876-3883
-
-
Massard, C.1
Fizazi, K.2
-
38
-
-
84866948935
-
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: Final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
-
Fizazi, K., Scher, H. I., Molina, A., et al. (2012). Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncology, 13, 983-992.
-
(2012)
Lancet Oncology
, vol.13
, pp. 983-992
-
-
Fizazi, K.1
Scher, H.I.2
Molina, A.3
-
39
-
-
84866770294
-
Increased survival with enzalutamide in prostate cancer after chemotherapy
-
Scher, H. I., Fizazi, K., Saad, F., et al. (2012). Increased survival with enzalutamide in prostate cancer after chemotherapy. New England Journal of Medicine, 367, 1187-1197.
-
(2012)
New England Journal of Medicine
, vol.367
, pp. 1187-1197
-
-
Scher, H.I.1
Fizazi, K.2
Saad, F.3
-
40
-
-
84881529561
-
Enzalutamide: A novel anti-androgen with prolonged survival rate in CRPC patients
-
Dhingra, R., Sharma, T., Singh, S., et al. (2013). Enzalutamide: a novel anti-androgen with prolonged survival rate in CRPC patients. Mini Reviews Medicinal Chemistry, 13, 1475-1486.
-
(2013)
Mini Reviews Medicinal Chemistry
, vol.13
, pp. 1475-1486
-
-
Dhingra, R.1
Sharma, T.2
Singh, S.3
-
41
-
-
79959282824
-
Translating scientific advancement into clinical benefit for castration-resistant prostate cancer patients
-
Attard, G., & de Bono, J. S. (2011). Translating scientific advancement into clinical benefit for castration-resistant prostate cancer patients. Clinical Cancer Research, 17, 3867-3875.
-
(2011)
Clinical Cancer Research
, vol.17
, pp. 3867-3875
-
-
Attard, G.1
De Bono, J.S.2
-
42
-
-
84883402878
-
Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial
-
Bahl, A., Oudard, S., Tombal, B., et al. (2013). Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial. Annals of Oncology, 24(9), 2402-8.
-
(2013)
Annals of Oncology
, vol.24
, Issue.9
, pp. 2402-2408
-
-
Bahl, A.1
Oudard, S.2
Tombal, B.3
-
43
-
-
77957682309
-
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial
-
de Bono, J. S., Oudard, S., Ozguroglu, M., et al. (2010). Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet, 376, 1147-1154.
-
(2010)
Lancet
, vol.376
, pp. 1147-1154
-
-
De Bono, J.S.1
Oudard, S.2
Ozguroglu, M.3
-
44
-
-
0033822572
-
Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: Predictive role of bone resorption and formation markers evaluated at baseline
-
Berruti, A., Dogliotti, L., Bitossi, R., et al. (2000). Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline. Journal of Urology, 164, 1248-1253.
-
(2000)
Journal of Urology
, vol.164
, pp. 1248-1253
-
-
Berruti, A.1
Dogliotti, L.2
Bitossi, R.3
-
45
-
-
0034085989
-
Metastatic patterns of prostate cancer: An autopsy study of 1,589 patients
-
Bubendorf, L., Schopfer, A., Wagner, U., et al. (2000). Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Human Pathology, 31, 578-583. (Pubitemid 30323983)
-
(2000)
Human Pathology
, vol.31
, Issue.5
, pp. 578-583
-
-
Bubendorf, L.1
Schopfer, A.2
Wagner, U.3
Sauter, G.4
Moch, H.5
Willi, N.6
Gasser, T.C.7
Mihatsch, M.J.8
-
46
-
-
84880428467
-
Alpha emitter radium-223 and survival in metastatic prostate cancer
-
Parker, C., Nilsson, S., Heinrich, D., et al. (2013). Alpha emitter radium-223 and survival in metastatic prostate cancer. New England Journal of Medicine, 369, 213-223.
-
(2013)
New England Journal of Medicine
, vol.369
, pp. 213-223
-
-
Parker, C.1
Nilsson, S.2
Heinrich, D.3
-
47
-
-
77953348723
-
CXCR4 and cancer
-
Furusato, B., Mohamed, A., Uhlen, M., & Rhim, J. S. (2010). CXCR4 and cancer. Pathology International, 60, 497-505.
-
(2010)
Pathology International
, vol.60
, pp. 497-505
-
-
Furusato, B.1
Mohamed, A.2
Uhlen, M.3
Rhim, J.S.4
-
48
-
-
78449300594
-
CXCL12/CXCR4/CXCR7 chemokine axis and cancer progression
-
Sun, X., Cheng, G., Hao, M., et al. (2010). CXCL12/CXCR4/CXCR7 chemokine axis and cancer progression. Cancer and Metastasis Reviews, 29, 709-722.
-
(2010)
Cancer and Metastasis Reviews
, vol.29
, pp. 709-722
-
-
Sun, X.1
Cheng, G.2
Hao, M.3
-
49
-
-
72749094682
-
Emerging roles of chemokines in prostate cancer
-
Vindrieux, D., Escobar, P., & Lazennec, G. (2009). Emerging roles of chemokines in prostate cancer. Endocrine-Related Cancer, 16, 663-673.
-
(2009)
Endocrine-Related Cancer
, vol.16
, pp. 663-673
-
-
Vindrieux, D.1
Escobar, P.2
Lazennec, G.3
-
50
-
-
69449096661
-
Induction of Kruppel-like factor 5 expression by androgens results in increased CXCR4-dependent migration of prostate cancer cells in vitro
-
Frigo, D. E., Sherk, A. B., Wittmann, B. M., et al. (2009). Induction of Kruppel-like factor 5 expression by androgens results in increased CXCR4-dependent migration of prostate cancer cells in vitro. Molecular Endocrinology, 23, 1385-1396.
-
(2009)
Molecular Endocrinology
, vol.23
, pp. 1385-1396
-
-
Frigo, D.E.1
Sherk, A.B.2
Wittmann, B.M.3
-
51
-
-
3142666166
-
CX3CR1-fractalkine expression regulates cellular mechanisms involved in adhesion, migration, and survival of human prostate cancer cells
-
DOI 10.1158/0008-5472.CAN-03-3437
-
Shulby, S. A., Dolloff, N. G., Stearns, M. E., Meucci, O., & Fatatis, A. (2004). CX3CR1-fractalkine expression regulates cellular mechanisms involved in adhesion, migration, and survival of human prostate cancer cells. Cancer Research, 64, 4693-4698. (Pubitemid 38924507)
-
(2004)
Cancer Research
, vol.64
, Issue.14
, pp. 4693-4698
-
-
Shulby, S.A.1
Dolloff, N.G.2
Stearns, M.E.3
Meucci, O.4
Fatatis, A.5
-
52
-
-
0033568470
-
Embryonic expression and function of the chemokine SDF-1 and its receptor, CXCR4
-
DOI 10.1006/dbio.1999.9405
-
McGrath, K. E., Koniski, A. D., Maltby, K. M., McGann, J. K.,&Palis, J. (1999). Embryonic expression and function of the chemokine SDF-1 and its receptor, CXCR4. Developmental Biology, 213, 442-456. (Pubitemid 29444352)
-
(1999)
Developmental Biology
, vol.213
, Issue.2
, pp. 442-456
-
-
McGrath, K.E.1
Koniski, A.D.2
Maltby, K.M.3
McGann, J.K.4
Palis, J.5
-
53
-
-
0038360798
-
Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo
-
DOI 10.1002/jcb.10522
-
Sun, Y. X., Wang, J., Shelburne, C. E., et al. (2003). Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo. Journal of Cellular Biochemistry, 89, 462-473. (Pubitemid 36648768)
-
(2003)
Journal of Cellular Biochemistry
, vol.89
, Issue.3
, pp. 462-473
-
-
Sun, Y.-X.1
Wang, J.2
Shelburne, C.E.3
Lopatin, D.E.4
Chinnaiyan, A.M.5
Rubin, M.A.6
Pienta, K.J.7
Taichman, R.S.8
-
54
-
-
19944433608
-
Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo
-
Sun, Y. X., Schneider, A., Jung, Y., et al. (2005). Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo. Journal of Bone and Mineral Research, 20, 318-329.
-
(2005)
Journal of Bone and Mineral Research
, vol.20
, pp. 318-329
-
-
Sun, Y.X.1
Schneider, A.2
Jung, Y.3
-
55
-
-
67650758019
-
Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer
-
Wang, Q., Li, W., Zhang, Y., et al. (2009). Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell, 138, 245-256.
-
(2009)
Cell
, vol.138
, pp. 245-256
-
-
Wang, Q.1
Li, W.2
Zhang, Y.3
-
56
-
-
79960071366
-
The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis
-
Massie, C. E., Lynch, A., Ramos-Montoya, A., et al. (2011). The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. EMBO Journal, 30, 2719-2733.
-
(2011)
EMBO Journal
, vol.30
, pp. 2719-2733
-
-
Massie, C.E.1
Lynch, A.2
Ramos-Montoya, A.3
-
57
-
-
84882285291
-
ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss
-
Chen, Y., Chi, P., Rockowitz, S., et al. (2013). ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss. Nature Medicine, 19, 1023-1029.
-
(2013)
Nature Medicine
, vol.19
, pp. 1023-1029
-
-
Chen, Y.1
Chi, P.2
Rockowitz, S.3
-
58
-
-
0037108766
-
Generation and characterization of androgen receptor knockout (ARKO) mice: An in vivo model for the study of androgen functions in selective tissues
-
DOI 10.1073/pnas.212474399
-
Yeh, S., Tsai, M. Y., Xu, Q., et al. (2002). Generation and characterization of androgen receptor knockout (ARKO) mice: an in vivo model for the study of androgen functions in selective tissues. Proceedings of the National Academy of Sciences of the United States of America, 99, 13498-13503. (Pubitemid 35215410)
-
(2002)
Proceedings of the National Academy of Sciences of the United States of America
, vol.99
, Issue.21
, pp. 13498-13503
-
-
Yeh, S.1
Tsai, M.-Y.2
Xu, Q.3
Mu, X.-M.4
Lardy, H.5
Huang, K.-E.6
Lin, H.7
Yeh, S.-D.8
Altuwaijri, S.9
Zhou, X.10
Xing, L.11
Boyce, B.F.12
Hung, M.-C.13
Zhang, S.14
Gan, L.15
Chang, C.16
-
59
-
-
40949139389
-
CX3CR1 is expressed by prostate epithelial cells and androgens regulate the levels of CX3CL1/fractalkine in the bone marrow: Potential role in prostate cancer bone tropism
-
DOI 10.1158/0008-5472.CAN-07-1315
-
Jamieson, W. L., Shimizu, S., D'Ambrosio, J. A., Meucci, O., & Fatatis, A. (2008). CX3CR1 is expressed by prostate epithelial cells and androgens regulate the levels of CX3CL1/fractalkine in the bone marrow: potential role in prostate cancer bone tropism. Cancer Research, 68, 1715-1722. (Pubitemid 351416556)
-
(2008)
Cancer Research
, vol.68
, Issue.6
, pp. 1715-1722
-
-
Jamieson, W.L.1
Shimizu, S.2
D'Ambrosio, J.A.3
Meucci, O.4
Fatatis, A.5
-
60
-
-
0032547581
-
3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion, and activation under physiologic flow
-
DOI 10.1084/jem.188.8.1413
-
Fong, A. M., Robinson, L. A., Steeber, D. A., et al. (1998). Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion, and activation under physiologic flow. Journal of Experimental Medicine, 188, 1413-1419. (Pubitemid 28489578)
-
(1998)
Journal of Experimental Medicine
, vol.188
, Issue.8
, pp. 1413-1419
-
-
Fong, A.M.1
Robinson, L.A.2
Steeber, D.A.3
Tedder, T.F.4
Yoshie, O.5
Imai, T.6
Patel, D.D.7
-
61
-
-
0034654653
-
3C-chemokine, fractalkine-enhanced adhesion of THP-1 cells to endothelial cells through integrin-dependent and -independent mechanisms
-
Goda, S., Imai, T., Yoshie, O., et al. (2000). CX3C-chemokine, fractalkine-enhanced adhesion of THP-1 cells to endothelial cells through integrin-dependent and -independent mechanisms. Journal of Immunology, 164, 4313-4320. (Pubitemid 30215094)
-
(2000)
Journal of Immunology
, vol.164
, Issue.8
, pp. 4313-4320
-
-
Goda, S.1
Imai, T.2
Yoshie, O.3
Yoneda, O.4
Inoue, H.5
Nagano, Y.6
Okazaki, T.7
Imai, H.8
Bloom, E.T.9
Domae, N.10
Umehara, H.11
-
62
-
-
0034743823
-
3C-chemokine, functions predominantly as an adhesion molecule in monocytic cell line THP-1
-
DOI 10.1046/j.1440-1711.2001.01004.x
-
Umehara, H., Goda, S., Imai, T., et al. (2001). Fractalkine, a CX3C-chemokine, functions predominantly as an adhesion molecule in monocytic cell line THP-1. Immunology and Cell Biology, 79, 298-302. (Pubitemid 32522179)
-
(2001)
Immunology and Cell Biology
, vol.79
, Issue.3
, pp. 298-302
-
-
Umehara, H.1
Goda, S.2
Imai, T.3
Nagano, Y.4
Minami, Y.5
Tanaka, Y.6
Okazaki, T.7
Bloom, E.T.8
Domae, N.9
-
63
-
-
40849085514
-
FoxA1 Translates Epigenetic Signatures into Enhancer-Driven Lineage-Specific Transcription
-
DOI 10.1016/j.cell.2008.01.018, PII S0092867408001189
-
Lupien, M., Eeckhoute, J., Meyer, C. A., et al. (2008). FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription. Cell, 132, 958-970. (Pubitemid 351391952)
-
(2008)
Cell
, vol.132
, Issue.6
, pp. 958-970
-
-
Lupien, M.1
Eeckhoute, J.2
Meyer, C.A.3
Wang, Q.4
Zhang, Y.5
Li, W.6
Carroll, J.S.7
Liu, X.S.8
Brown, M.9
-
64
-
-
67650480389
-
Cistromics of hormone-dependent cancer
-
Lupien, M., & Brown, M. (2009). Cistromics of hormone-dependent cancer. Endocrine-Related Cancer, 16, 381-389.
-
(2009)
Endocrine-Related Cancer
, vol.16
, pp. 381-389
-
-
Lupien, M.1
Brown, M.2
-
65
-
-
79953319002
-
Epigenetic switch involved in activation of pioneer factor FOXA1-dependent enhancers
-
Serandour, A. A., Avner, S., Percevault, F., et al. (2011). Epigenetic switch involved in activation of pioneer factor FOXA1-dependent enhancers. Genome Research, 21, 555-565.
-
(2011)
Genome Research
, vol.21
, pp. 555-565
-
-
Serandour, A.A.1
Avner, S.2
Percevault, F.3
-
66
-
-
67649208317
-
Coactivator function defines the active estrogen receptor alpha cistrome
-
Lupien, M., Eeckhoute, J., Meyer, C. A., et al. (2009). Coactivator function defines the active estrogen receptor alpha cistrome. Molecular and Cellular Biology, 29, 3413-3423.
-
(2009)
Molecular and Cellular Biology
, vol.29
, pp. 3413-3423
-
-
Lupien, M.1
Eeckhoute, J.2
Meyer, C.A.3
-
67
-
-
84874507326
-
FoxA1 is a key mediator of hormonal response in breast and prostate cancer
-
Robinson, J. L., & Carroll, J. S. (2012). FoxA1 is a key mediator of hormonal response in breast and prostate cancer. Frontiers Endocrinology (Lausanne), 3, 68.
-
(2012)
Frontiers Endocrinology (Lausanne)
, vol.3
, pp. 68
-
-
Robinson, J.L.1
Carroll, J.S.2
-
68
-
-
84874918445
-
FoxA1 specifies unique androgen and glucocorticoid receptor binding events in prostate cancer cells
-
Sahu, B., Laakso, M., Pihlajamaa, P., et al. (2013). FoxA1 specifies unique androgen and glucocorticoid receptor binding events in prostate cancer cells. Cancer Research, 73, 1570-1580.
-
(2013)
Cancer Research
, vol.73
, pp. 1570-1580
-
-
Sahu, B.1
Laakso, M.2
Pihlajamaa, P.3
-
69
-
-
80053610846
-
Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer
-
Sahu, B., Laakso, M., Ovaska, K., et al. (2011). Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer. EMBO Journal, 30, 3962-3976.
-
(2011)
EMBO Journal
, vol.30
, pp. 3962-3976
-
-
Sahu, B.1
Laakso, M.2
Ovaska, K.3
-
70
-
-
80053611688
-
FOXA1: Master of steroid receptor function in cancer
-
Augello, M. A., Hickey, T. E., & Knudsen, K. E. (2011). FOXA1: master of steroid receptor function in cancer. EMBO Journal, 30, 3885-3894.
-
(2011)
EMBO Journal
, vol.30
, pp. 3885-3894
-
-
Augello, M.A.1
Hickey, T.E.2
Knudsen, K.E.3
-
71
-
-
80155126691
-
Definition of a FoxA1 cistrome that is crucial for G1 to S-phase cell-cycle transit in castration-resistant prostate cancer
-
Zhang, C., Wang, L., Wu, D., et al. (2011). Definition of a FoxA1 cistrome that is crucial for G1 to S-phase cell-cycle transit in castration-resistant prostate cancer. Cancer Research, 71, 6738-6748.
-
(2011)
Cancer Research
, vol.71
, pp. 6738-6748
-
-
Zhang, C.1
Wang, L.2
Wu, D.3
-
72
-
-
84855987529
-
FOXA1 promotes tumor progression in prostate cancer and represents a novel hall-mark of castration-resistant prostate cancer
-
Gerhardt, J., Montani, M., Wild, P., et al. (2012). FOXA1 promotes tumor progression in prostate cancer and represents a novel hall-mark of castration-resistant prostate cancer. American Journal of Pathology, 180, 848-861.
-
(2012)
American Journal of Pathology
, vol.180
, pp. 848-861
-
-
Gerhardt, J.1
Montani, M.2
Wild, P.3
-
73
-
-
84879085247
-
Androgen receptor-independent function of FoxA1 in prostate cancer metastasis
-
Jin, H. J., Zhao, J. C., Ogden, I., Bergan, R. C., & Yu, J. (2013). Androgen receptor-independent function of FoxA1 in prostate cancer metastasis. Cancer Research, 73, 3725-3736.
-
(2013)
Cancer Research
, vol.73
, pp. 3725-3736
-
-
Jin, H.J.1
Zhao, J.C.2
Ogden, I.3
Bergan, R.C.4
Yu, J.5
-
74
-
-
79954568222
-
High-level expression of forkhead-box protein A1 in metastatic prostate cancer
-
Jain, R. K., Mehta, R. J., Nakshatri, H., Idrees, M. T.,& Badve, S. S. (2011). High-level expression of forkhead-box protein A1 in metastatic prostate cancer. Histopathology, 58, 766-772.
-
(2011)
Histopathology
, vol.58
, pp. 766-772
-
-
Jain, R.K.1
Mehta, R.J.2
Nakshatri, H.3
Idrees, M.T.4
Badve, S.S.5
-
75
-
-
84863723010
-
The mutational landscape of lethal castration-resistant prostate cancer
-
Grasso, C. S., Wu, Y. M., Robinson, D. R., et al. (2012). The mutational landscape of lethal castration-resistant prostate cancer. Nature, 487, 239-243.
-
(2012)
Nature
, vol.487
, pp. 239-243
-
-
Grasso, C.S.1
Wu, Y.M.2
Robinson, D.R.3
-
76
-
-
84861581164
-
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer
-
Barbieri, C. E., Baca, S. C., Lawrence, M. S., et al. (2012). Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nature Genetics, 44, 685-689.
-
(2012)
Nature Genetics
, vol.44
, pp. 685-689
-
-
Barbieri, C.E.1
Baca, S.C.2
Lawrence, M.S.3
-
77
-
-
84890665224
-
FOXA1 mutations in hormone-dependent cancers
-
Robinson, J. L., Holmes, K. A., & Carroll, J. S. (2013). FOXA1 mutations in hormone-dependent cancers. Frontiers Oncology, 3, 20.
-
(2013)
Frontiers Oncology
, vol.3
, pp. 20
-
-
Robinson, J.L.1
Holmes, K.A.2
Carroll, J.S.3
-
78
-
-
84555204370
-
Diverse functions of ATP-dependent chromatin remodeling complexes in development and cancer
-
Wu, J. I. (2012). Diverse functions of ATP-dependent chromatin remodeling complexes in development and cancer. Acta Biochimica Biophysica Sinica (Shanghai), 44, 54-69.
-
(2012)
Acta Biochimica Biophysica Sinica (Shanghai)
, vol.44
, pp. 54-69
-
-
Wu, J.I.1
-
79
-
-
70350539592
-
Hijacking the chromatin remodeling machinery: Impact of SWI/SNF perturbations in cancer
-
Weissman, B., & Knudsen, K. E. (2009). Hijacking the chromatin remodeling machinery: impact of SWI/SNF perturbations in cancer. Cancer Research, 69, 8223-8230.
-
(2009)
Cancer Research
, vol.69
, pp. 8223-8230
-
-
Weissman, B.1
Knudsen, K.E.2
-
80
-
-
58249086425
-
Understanding the words of chromatin regulation
-
Wu, J. I., Lessard, J., & Crabtree, G. R. (2009). Understanding the words of chromatin regulation. Cell, 136, 200-206.
-
(2009)
Cell
, vol.136
, pp. 200-206
-
-
Wu, J.I.1
Lessard, J.2
Crabtree, G.R.3
-
81
-
-
49649117206
-
Targeting the BAF57 SWI/SNF subunit in prostate cancer: A novel platform to control androgen receptor activity
-
Link, K. A., Balasubramaniam, S., Sharma, A., et al. (2008). Targeting the BAF57 SWI/SNF subunit in prostate cancer: a novel platform to control androgen receptor activity. Cancer Research, 68, 4551-4558.
-
(2008)
Cancer Research
, vol.68
, pp. 4551-4558
-
-
Link, K.A.1
Balasubramaniam, S.2
Sharma, A.3
-
82
-
-
84878042268
-
Aberrant BAF57 signaling facilitates prometastatic phenotypes
-
Balasubramaniam, S., Comstock, C. E., Ertel, A., et al. (2013). Aberrant BAF57 signaling facilitates prometastatic phenotypes. Clinical Cancer Research, 19, 2657-2667.
-
(2013)
Clinical Cancer Research
, vol.19
, pp. 2657-2667
-
-
Balasubramaniam, S.1
Comstock, C.E.2
Ertel, A.3
-
83
-
-
14844364364
-
BAF57 governs androgen receptor action and androgen-dependent proliferation through SWI/SNF
-
DOI 10.1128/MCB.25.6.2200-2215.2005
-
Link, K. A., Burd, C. J., Williams, E., et al. (2005). BAF57 governs androgen receptor action and androgen-dependent proliferation through SWI/SNF. Molecular and Cellular Biology, 25, 2200-2215. (Pubitemid 40354619)
-
(2005)
Molecular and Cellular Biology
, vol.25
, Issue.6
, pp. 2200-2215
-
-
Link, K.A.1
Burd, C.J.2
Williams, E.3
Marshall, T.4
Rosson, G.5
Henry, E.6
Weissman, B.7
Knudsen, K.E.8
-
84
-
-
33845394286
-
The cyclin D1b splice variant: An old oncogene learns new tricks
-
Knudsen, K. E. (2006). The cyclin D1b splice variant: an old oncogene learns new tricks. Cell Division, 1, 15.
-
(2006)
Cell Division
, vol.1
, pp. 15
-
-
Knudsen, K.E.1
-
85
-
-
0242526150
-
An Alternatively Spliced Cyclin D1 Isoform, Cyclin D1b, Is a Nuclear Oncogene
-
Lu, F., Gladden, A. B., & Diehl, J. A. (2003). An alternatively spliced cyclin D1 isoform, cyclin D1b, is a nuclear oncogene. Cancer Research, 63, 7056-7061. (Pubitemid 37413439)
-
(2003)
Cancer Research
, vol.63
, Issue.21
, pp. 7056-7061
-
-
Lu, F.1
Gladden, A.B.2
Diehl, J.A.3
-
86
-
-
70349912696
-
Cyclin D1b variant promotes cell invasiveness independent of binding to CDK4 in human bladder cancer cells
-
Kim, C. J., Nishi, K., Isono, T., et al. (2009). Cyclin D1b variant promotes cell invasiveness independent of binding to CDK4 in human bladder cancer cells. Molecular Carcinogenesis, 48, 953-964.
-
(2009)
Molecular Carcinogenesis
, vol.48
, pp. 953-964
-
-
Kim, C.J.1
Nishi, K.2
Isono, T.3
-
87
-
-
48649103464
-
Cyclin D1b is aberrantly regulated in response to therapeutic challenge and promotes resistance to estrogen antagonists
-
Wang, Y., Dean, J. L., Millar, E. K., et al. (2008). Cyclin D1b is aberrantly regulated in response to therapeutic challenge and promotes resistance to estrogen antagonists. Cancer Research, 68, 5628-5638.
-
(2008)
Cancer Research
, vol.68
, pp. 5628-5638
-
-
Wang, Y.1
Dean, J.L.2
Millar, E.K.3
-
88
-
-
14844333265
-
2-terminal domain inhibits activation function 2 association and reveals dual roles for AR corepression
-
DOI 10.1210/me.2004-0266
-
Burd, C. J., Petre, C. E., Moghadam, H., Wilson, E. M., & Knudsen, K. E. (2005). Cyclin D1 binding to the androgen receptor (AR) NH2-terminal domain inhibits activation function 2 association and reveals dual roles forAR corepression. Molecular Endocrinology, 19, 607-620. (Pubitemid 40349435)
-
(2005)
Molecular Endocrinology
, vol.19
, Issue.3
, pp. 607-620
-
-
Burd, C.J.1
Petre, C.E.2
Moghadam, H.3
Wilson, E.M.4
Knudsen, K.E.5
-
89
-
-
79953153894
-
Cyclin D1 is a selective modifier of androgen-dependent signaling and androgen receptor function
-
Comstock, C. E., Augello, M. A., Schiewer, M. J., et al. (2011). Cyclin D1 is a selective modifier of androgen-dependent signaling and androgen receptor function. Journal of Biological Chemistry, 286, 8117-8127.
-
(2011)
Journal of Biological Chemistry
, vol.286
, pp. 8117-8127
-
-
Comstock, C.E.1
Augello, M.A.2
Schiewer, M.J.3
-
90
-
-
0037127320
-
Cyclin D1: Mechanism and consequence of androgen receptor co-repressor activity
-
DOI 10.1074/jbc.M106399200
-
Petre, C. E., Wetherill, Y. B., Danielsen, M., & Knudsen, K. E. (2002). Cyclin D1: mechanism and consequence of androgen receptor corepressor activity. Journal of Biological Chemistry, 277, 2207-2215. (Pubitemid 34968808)
-
(2002)
Journal of Biological Chemistry
, vol.277
, Issue.3
, pp. 2207-2215
-
-
Petre, C.E.1
Wetherill, Y.B.2
Danielsen, M.3
Knudsen, K.E.4
-
91
-
-
13244256871
-
A central domain of cyclin D1 mediates nuclear receptor corepressor activity
-
DOI 10.1038/sj.onc.1208200
-
Petre-Draviam, C. E., Williams, E. B., Burd, C. J., et al. (2005). A central domain of cyclin D1 mediates nuclear receptor corepressor activity. Oncogene, 24, 431-444. (Pubitemid 40188591)
-
(2005)
Oncogene
, vol.24
, Issue.3
, pp. 431-444
-
-
Petre-Draviam, C.E.1
Williams, E.B.2
Burd, C.J.3
Gladden, A.4
Moghadam, H.5
Meller, J.6
Diehl, J.A.7
Knudsen, K.E.8
-
92
-
-
33144474074
-
Cyclin D1b variant influences prostate cancer growth through aberrant androgen receptor regulation
-
DOI 10.1073/pnas.0506281103
-
Burd, C. J., Petre, C. E., Morey, L. M., et al. (2006). Cyclin D1b variant influences prostate cancer growth through aberrant androgen receptor regulation. Proceedings of the National Academy of Sciences of the United States of America, 103, 2190-2195. (Pubitemid 43271645)
-
(2006)
Proceedings of the National Academy of Sciences of the United States of America
, vol.103
, Issue.7
, pp. 2190-2195
-
-
Burd, C.J.1
Petre, C.E.2
Morey, L.M.3
Wang, Y.4
Revelo, M.P.5
Haiman, C.A.6
Lu, S.7
Fenoglio-Preiser, C.M.8
Li, J.9
Knudsen, E.S.10
Wong, J.11
Knudsen, K.E.12
-
93
-
-
33645118564
-
Cyclin D1: Polymorphism, aberrant splicing and cancer risk
-
Knudsen, K. E., Diehl, J. A., Haiman, C. A., & Knudsen, E. S. (2006). Cyclin D1: polymorphism, aberrant splicing and cancer risk. Oncogene, 25, 1620-1628.
-
(2006)
Oncogene
, vol.25
, pp. 1620-1628
-
-
Knudsen, K.E.1
Diehl, J.A.2
Haiman, C.A.3
Knudsen, E.S.4
-
94
-
-
84873872188
-
Convergence of oncogenic and hormone receptor pathways promotes metastatic phenotypes
-
Augello, M. A., Burd, C. J., Birbe, R., et al. (2013). Convergence of oncogenic and hormone receptor pathways promotes metastatic phenotypes. Journal of Clinical Investigation, 123, 493-508.
-
(2013)
Journal of Clinical Investigation
, vol.123
, pp. 493-508
-
-
Augello, M.A.1
Burd, C.J.2
Birbe, R.3
-
95
-
-
77954637769
-
Slug/SNAI2 regulates cell proliferation and invasiveness of metastatic prostate cancer cell lines
-
Emadi Baygi, M., Soheili, Z. S., Essmann, F., et al. (2010). Slug/SNAI2 regulates cell proliferation and invasiveness of metastatic prostate cancer cell lines. Tumour Biology, 31, 297-307.
-
(2010)
Tumour Biology
, vol.31
, pp. 297-307
-
-
Emadi Baygi, M.1
Soheili, Z.S.2
Essmann, F.3
-
96
-
-
84865582502
-
Slug, a unique androgen-regulated transcription factor, coordinates androgen receptor to facilitate castration resistance in prostate cancer
-
Wu, K., Gore, C., Yang, L., et al. (2012). Slug, a unique androgen-regulated transcription factor, coordinates androgen receptor to facilitate castration resistance in prostate cancer. Molecular Endocrinology, 26, 1496-1507.
-
(2012)
Molecular Endocrinology
, vol.26
, pp. 1496-1507
-
-
Wu, K.1
Gore, C.2
Yang, L.3
-
97
-
-
84905110156
-
Liver metastases (LM) to predict for short overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts)
-
Chicago, IL: Journal of Clinical Oncology; p. Abstract 4655
-
Kelly WK HS, Carducci MA, et al. (2012). Liver metastases (LM) to predict for short overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts). 2012 ASCO Annual Meeting. Chicago, IL: Journal of Clinical Oncology; p. Abstract 4655.
-
(2012)
2012 ASCO Annual Meeting
-
-
Kelly, W.K.H.S.1
Carducci, M.A.2
-
98
-
-
35648948853
-
TMPRSS2-ERG Fusion Heterogeneity in Multifocal Prostate Cancer: Clinical and Biologic Implications
-
DOI 10.1016/j.urology.2007.08.032, PII S0090429507020146
-
Barry, M., Perner, S., Demichelis, F., & Rubin, M. A. (2007). TMPRSS2-ERG fusion heterogeneity in multifocal prostate cancer: clinical and biologic implications. Urology, 70, 630-633. (Pubitemid 350030260)
-
(2007)
Urology
, vol.70
, Issue.4
, pp. 630-633
-
-
Barry, M.1
Perner, S.2
Demichelis, F.3
Rubin, M.A.4
-
99
-
-
79951497419
-
The genomic complexity of primary human prostate cancer
-
Berger, M. F., Lawrence, M. S., Demichelis, F., et al. (2011). The genomic complexity of primary human prostate cancer. Nature, 470, 214-220.
-
(2011)
Nature
, vol.470
, pp. 214-220
-
-
Berger, M.F.1
Lawrence, M.S.2
Demichelis, F.3
-
100
-
-
34247363715
-
Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer
-
DOI 10.1038/modpathol.3800769, PII 3800769
-
Mehra, R., Tomlins, S. A., Shen, R., et al. (2007). Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Modern Pathology, 20, 538-544. (Pubitemid 46631996)
-
(2007)
Modern Pathology
, vol.20
, Issue.5
, pp. 538-544
-
-
Mehra, R.1
Tomlins, S.A.2
Shen, R.3
Nadeem, O.4
Wang, L.5
Wei, J.T.6
Pienta, K.J.7
Ghosh, D.8
Rubin, M.A.9
Chinnaiyan, A.M.10
Shah, R.B.11
-
101
-
-
68049101459
-
Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States
-
Mosquera, J. M., Mehra, R., Regan, M. M., et al. (2009). Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States. Clinical Cancer Research, 15, 4706-4711.
-
(2009)
Clinical Cancer Research
, vol.15
, pp. 4706-4711
-
-
Mosquera, J.M.1
Mehra, R.2
Regan, M.M.3
-
102
-
-
67649425225
-
ETS gene fusions in prostate cancer: From discovery to daily clinical practice
-
Tomlins, S. A., Bjartell, A., Chinnaiyan, A. M., et al. (2009). ETS gene fusions in prostate cancer: from discovery to daily clinical practice. European Urology, 56, 275-286.
-
(2009)
European Urology
, vol.56
, pp. 275-286
-
-
Tomlins, S.A.1
Bjartell, A.2
Chinnaiyan, A.M.3
-
103
-
-
34547642493
-
Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer
-
DOI 10.1038/nature06024, PII NATURE06024
-
Tomlins, S. A., Laxman, B., Dhanasekaran, S. M., et al. (2007). Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature, 448, 595-599. (Pubitemid 47206938)
-
(2007)
Nature
, vol.448
, Issue.7153
, pp. 595-599
-
-
Tomlins, S.A.1
Laxman, B.2
Dhanasekaran, S.M.3
Helgeson, B.E.4
Cao, X.5
Morris, D.S.6
Menon, A.7
Jing, X.8
Cao, Q.9
Han, B.10
Yu, J.11
Wang, L.12
Montie, J.E.13
Rubin, M.A.14
Pienta, K.J.15
Roulston, D.16
Shah, R.B.17
Varambally, S.18
Mehra, R.19
Chinnaiyan, A.M.20
more..
-
104
-
-
84873607610
-
Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer
-
Weischenfeldt, J., Simon, R., Feuerbach, L., et al. (2013). Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer. Cancer Cell, 23, 159-170.
-
(2013)
Cancer Cell
, vol.23
, pp. 159-170
-
-
Weischenfeldt, J.1
Simon, R.2
Feuerbach, L.3
-
105
-
-
39049170313
-
Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer
-
DOI 10.1158/0008-5472.CAN-07-5352
-
Helgeson, B. E., Tomlins, S. A., Shah, N., et al. (2008). Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer. Cancer Research, 68, 73-80. (Pubitemid 351380107)
-
(2008)
Cancer Research
, vol.68
, Issue.1
, pp. 73-80
-
-
Helgeson, B.E.1
Tomlins, S.A.2
Shah, N.3
Laxman, B.4
Cao, Q.5
Prensner, J.R.6
Cao, X.7
Singla, N.8
Montie, J.E.9
Varambally, S.10
Mehra, R.11
Chinnaiyan, A.M.12
-
106
-
-
45849103492
-
Recurrent gene fusions in prostate cancer
-
Kumar-Sinha, C., Tomlins, S. A., & Chinnaiyan, A. M. (2008). Recurrent gene fusions in prostate cancer. Nature Reviews Cancer, 8, 497-511.
-
(2008)
Nature Reviews Cancer
, vol.8
, pp. 497-511
-
-
Kumar-Sinha, C.1
Tomlins, S.A.2
Chinnaiyan, A.M.3
-
107
-
-
70849135782
-
Induced chromosomal proximity and gene fusions in prostate cancer
-
Mani, R. S., Tomlins, S. A., Callahan, K., et al. (2009). Induced chromosomal proximity and gene fusions in prostate cancer. Science, 326, 1230.
-
(2009)
Science
, vol.326
, pp. 1230
-
-
Mani, R.S.1
Tomlins, S.A.2
Callahan, K.3
-
108
-
-
71249101060
-
Nuclear receptor-induced chromosomal proximity and DNA breaks underlie specific translocations in cancer
-
Lin, C., Yang, L., Tanasa, B., et al. (2009). Nuclear receptor-induced chromosomal proximity and DNA breaks underlie specific translocations in cancer. Cell, 139, 1069-1083.
-
(2009)
Cell
, vol.139
, pp. 1069-1083
-
-
Lin, C.1
Yang, L.2
Tanasa, B.3
-
109
-
-
34248510706
-
TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort
-
DOI 10.1038/sj.onc.1210237, PII 1210237
-
Demichelis, F., Fall, K., Perner, S., et al. (2007). TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene, 26, 4596-4599. (Pubitemid 47037039)
-
(2007)
Oncogene
, vol.26
, Issue.31
, pp. 4596-4599
-
-
Demichelis, F.1
Fall, K.2
Perner, S.3
Andren, O.4
Schmidt, F.5
Setlur, S.R.6
Hoshida, Y.7
Mosquera, J.-M.8
Pawitan, Y.9
Lee, C.10
Adami, H.-O.11
Mucci, L.A.12
Kantoff, P.W.13
Andersson, S.-O.14
Chinnaiyan, A.M.15
Johansson, J.-E.16
Rubin, M.A.17
-
110
-
-
39049150843
-
Role of the TMPRSS2-ERG gene fusion in prostate cancer
-
DOI 10.1593/neo.07822
-
Tomlins, S. A., Laxman, B., Varambally, S., et al. (2008). Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia, 10, 177-188. (Pubitemid 351240884)
-
(2008)
Neoplasia
, vol.10
, Issue.2
, pp. 177-188
-
-
Tomlins, S.A.1
Laxman, B.2
Varambally, S.3
Cao, X.4
Yu, J.5
Helgeson, B.E.6
Cao, Q.7
Prensner, J.R.8
Rubin, M.A.9
Shah, R.B.10
Mehra, R.11
Chinnaiyan, A.M.12
-
111
-
-
66749100105
-
Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis
-
King, J. C., Xu, J., Wongvipat, J., et al. (2009). Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nature Genetics, 41, 524-526.
-
(2009)
Nature Genetics
, vol.41
, pp. 524-526
-
-
King, J.C.1
Xu, J.2
Wongvipat, J.3
-
112
-
-
77952103123
-
An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression
-
Yu, J., Mani, R. S., Cao, Q., et al. (2010). An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell, 17, 443-454.
-
(2010)
Cancer Cell
, vol.17
, pp. 443-454
-
-
Yu, J.1
Mani, R.S.2
Cao, Q.3
-
113
-
-
18644382388
-
The polycomb group protein EZH2 is involved in progression of prostate cancer
-
Varambally, S., Dhanasekaran, S. M., Zhou, M., et al. (2002). The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature, 419, 624-629.
-
(2002)
Nature
, vol.419
, pp. 624-629
-
-
Varambally, S.1
Dhanasekaran, S.M.2
Zhou, M.3
-
114
-
-
36349017912
-
A polycomb repression signature in metastatic prostate cancer predicts cancer outcome
-
DOI 10.1158/0008-5472.CAN-07-2498
-
Yu, J., Rhodes, D. R., Tomlins, S. A., et al. (2007). A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. Cancer Research, 67, 10657-10663. (Pubitemid 350145890)
-
(2007)
Cancer Research
, vol.67
, Issue.22
, pp. 10657-10663
-
-
Yu, J.1
Yu, J.2
Rhodes, D.R.3
Tomlins, S.A.4
Cao, X.5
Chen, G.6
Mehra, R.7
Wang, X.8
Ghosh, D.9
Shah, R.B.10
Varambally, S.11
Pienta, K.J.12
Chinnaiyan, A.M.13
-
115
-
-
84871052080
-
EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent
-
Xu, K., Wu, Z. J., Groner, A. C., et al. (2012). EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent. Science, 338, 1465-1469.
-
(2012)
Science
, vol.338
, pp. 1465-1469
-
-
Xu, K.1
Wu, Z.J.2
Groner, A.C.3
-
116
-
-
0036696817
-
Twenty pairs of sox: Extent, homology, and nomenclature of the mouse and human sox transcription factor gene families
-
Schepers, G. E., Teasdale, R. D.,&Koopman, P. (2002). Twenty pairs of sox: extent, homology, and nomenclature of the mouse and human sox transcription factor gene families. Developmental Cell, 3, 167-170.
-
(2002)
Developmental Cell
, vol.3
, pp. 167-170
-
-
Schepers, G.E.1
Teasdale, R.D.2
Koopman, P.3
-
117
-
-
79952455908
-
Understanding the role of SOX9 in acquired diseases: Lessons from development
-
Pritchett, J., Athwal, V., Roberts, N., Hanley, N. A., & Hanley, K. P. (2011). Understanding the role of SOX9 in acquired diseases: lessons from development. Trends in Molecular Medicine, 17, 166-174.
-
(2011)
Trends in Molecular Medicine
, vol.17
, pp. 166-174
-
-
Pritchett, J.1
Athwal, V.2
Roberts, N.3
Hanley, N.A.4
Hanley, K.P.5
-
118
-
-
33846910410
-
SOX9 is required for maintenance of the pancreatic progenitor cell pool
-
DOI 10.1073/pnas.0609217104
-
Seymour, P. A., Freude, K. K., Tran, M. N., et al. (2007). SOX9 is required for maintenance of the pancreatic progenitor cell pool. Proceedings of the National Academy of Sciences of the United States of America, 104, 1865-1870. (Pubitemid 46239870)
-
(2007)
Proceedings of the National Academy of Sciences of the United States of America
, vol.104
, Issue.6
, pp. 1865-1870
-
-
Seymour, P.A.1
Freude, K.K.2
Tran, M.N.3
Mayes, E.E.4
Jensen, J.5
Kist, R.6
Scherer, G.7
Sander, M.8
-
119
-
-
84865277434
-
A Sox9/Fgf feed-forward loop maintains pancreatic organ identity
-
Seymour, P. A., Shih, H. P., Patel, N. A., et al. (2012). A Sox9/Fgf feed-forward loop maintains pancreatic organ identity. Development, 139, 3363-3372.
-
(2012)
Development
, vol.139
, pp. 3363-3372
-
-
Seymour, P.A.1
Shih, H.P.2
Patel, N.A.3
-
120
-
-
78651228289
-
Continuous cell supply from a Sox9-expressing progenitor zone in adult liver, exocrine pancreas and intestine
-
Furuyama, K., Kawaguchi, Y., Akiyama, H., et al. (2011). Continuous cell supply from a Sox9-expressing progenitor zone in adult liver, exocrine pancreas and intestine. Nature Genetics, 43, 34-41.
-
(2011)
Nature Genetics
, vol.43
, pp. 34-41
-
-
Furuyama, K.1
Kawaguchi, Y.2
Akiyama, H.3
-
121
-
-
41149136532
-
Sox9 is required for prostate development
-
Thomsen, M. K., Butler, C. M., Shen, M. M., & Swain, A. (2008). Sox9 is required for prostate development. Developmental Biology, 316, 302-311.
-
(2008)
Developmental Biology
, vol.316
, pp. 302-311
-
-
Thomsen, M.K.1
Butler, C.M.2
Shen, M.M.3
Swain, A.4
-
122
-
-
76249098305
-
SOX9 elevation in the prostate promotes proliferation and cooperates with PTEN loss to drive tumor formation
-
Thomsen, M. K., Ambroisine, L., Wynn, S., et al. (2010). SOX9 elevation in the prostate promotes proliferation and cooperates with PTEN loss to drive tumor formation. Cancer Research, 70, 979-987.
-
(2010)
Cancer Research
, vol.70
, pp. 979-987
-
-
Thomsen, M.K.1
Ambroisine, L.2
Wynn, S.3
-
123
-
-
40949145618
-
SOX9 is expressed in human fetal prostate epithelium and enhances prostate cancer invasion
-
DOI 10.1158/0008-5472.CAN-07-5915
-
Wang, H., Leav, I., Ibaragi, S., et al. (2008). SOX9 is expressed in human fetal prostate epithelium and enhances prostate cancer invasion. Cancer Research, 68, 1625-1630. (Pubitemid 351416545)
-
(2008)
Cancer Research
, vol.68
, Issue.6
, pp. 1625-1630
-
-
Wang, H.1
Leav, I.2
Ibaragi, S.3
Wegner, M.4
Hu, G.-F.5
Lu, M.L.6
Balk, S.P.7
Yuan, X.8
-
124
-
-
84874598190
-
ERG induces androgen receptor-mediated regulation of SOX9 in prostate cancer
-
Cai, C., Wang, H., He, H. H., et al. (2013). ERG induces androgen receptor-mediated regulation of SOX9 in prostate cancer. Journal of Clinical Investigation, 123, 1109-1122.
-
(2013)
Journal of Clinical Investigation
, vol.123
, pp. 1109-1122
-
-
Cai, C.1
Wang, H.2
He, H.H.3
-
125
-
-
79953099043
-
Immunotherapy in castration-resistant prostate cancer: Integrating sipuleucel-T into our current treatment paradigm
-
Garcia, J. A., & Dreicer, R. (2011). Immunotherapy in castration-resistant prostate cancer: integrating sipuleucel-T into our current treatment paradigm. Oncology (Williston Park), 25, 242-249.
-
(2011)
Oncology (Williston Park)
, vol.25
, pp. 242-249
-
-
Garcia, J.A.1
Dreicer, R.2
-
126
-
-
34548740289
-
Neoadjuvant docetaxel treatment for locally advanced prostate cancer: A clinicopathologic study
-
DOI 10.1002/cncr.22897
-
Magi-Galluzzi, C., Zhou, M., Reuther, A. M., Dreicer, R., & Klein, E. A. (2007). Neoadjuvant docetaxel treatment for locally advanced prostate cancer: a clinicopathologic study. Cancer, 110, 1248-1254. (Pubitemid 47435595)
-
(2007)
Cancer
, vol.110
, Issue.6
, pp. 1248-1254
-
-
Magi-Galluzzi, C.1
Zhou, M.2
Reuther, A.M.3
Dreicer, R.4
Klein, E.A.5
-
127
-
-
78649523986
-
Safety, pharmacokinetics, and efficacy of TAK-700 in metastatic castration-resistant prostate cancer: A phase I/II, open-label study
-
abstr 3084 2010.
-
Dreicer, R., Agus, D. B., MacVicar, G. R., Wang, J., MacLean, D., & Stadler, W. M. (2010). Safety, pharmacokinetics, and efficacy of TAK-700 in metastatic castration-resistant prostate cancer: a phase I/II, open-label study. Journal of Clinical Oncology, 28, 15s. (suppl; abstr 3084) 2010.
-
(2010)
Journal of Clinical Oncology
, vol.28
, Issue.SUPPL.
-
-
Dreicer, R.1
Agus, D.B.2
MacVicar, G.R.3
Wang, J.4
MacLean, D.5
Stadler, W.M.6
-
128
-
-
84872078210
-
Abiraterone in metastatic prostate cancer without previous chemotherapy
-
Ryan, C. J., Smith, M. R., de Bono, J. S., et al. (2013). Abiraterone in metastatic prostate cancer without previous chemotherapy. New England Journal of Medicine, 368, 138-148.
-
(2013)
New England Journal of Medicine
, vol.368
, pp. 138-148
-
-
Ryan, C.J.1
Smith, M.R.2
De Bono, J.S.3
-
129
-
-
79952734485
-
A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors
-
Pacey, S., Wilson, R. H., Walton, M., et al. (2011). A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors. Clinical Cancer Research, 17, 1561-1570.
-
(2011)
Clinical Cancer Research
, vol.17
, pp. 1561-1570
-
-
Pacey, S.1
Wilson, R.H.2
Walton, M.3
|